MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

Strona główna・Stock List・AnaptysBio Inc

AnaptysBio Inc

Closed

SectorHealthcare

68.49 4.89

Buy Sell

Overview

Share price change

24h

Current

Min

63.88

Max

Key metrics
By Trading Economics
Income	35M 50M
Sales	32M 108M
Profit margin	45.833
Employees	104
EBITDA	29M 68M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+26.98% upside

Dividends
By Dow Jones
Next Earnings	1 maj 2026

Market Stats
By TradingEconomics
Market Cap	259M 1.8B
Previous open	63.6
Previous close	68.49

News Sentiment

By Acuity

47%

53%

158 / 348 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

19.25 / 21.135 Support & Resistance

AnaptysBio Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

10 kwi 2026, 00:00 UTC

Major News Events

ADB: Higher Energy Prices to Raise Production, Consumer Costs

10 kwi 2026, 00:00 UTC

Major News Events

ADB Projects Japan GDP Growth at 0.7% in 2026, 0.6% in 2027

10 kwi 2026, 00:00 UTC

Major News Events

ADB Projects South Korea GDP Growth at 1.9% in 2026, 1.9% in 2027

10 kwi 2026, 00:00 UTC

Major News Events

Extent of Slowdown Hinges on Duration of MidEast Conflict, ADB Says

10 kwi 2026, 00:00 UTC

Major News Events

ADB Projects India GDP Growth at 6.9% in 2026, 7.3% in 2027

10 kwi 2026, 00:00 UTC

Major News Events

ADB Projects China GDP Growth at 4.6% in 2026, 4.5% in 2027

10 kwi 2026, 00:00 UTC

Major News Events

ADB Pojects Australia GDP Grrowth at 2.0% in 2026, 2.9% in 2027

10 kwi 2026, 00:00 UTC

Major News Events

ADB Projects Taiwan GDP Growth at 7.6% in 2026, 4.0% in 2027

10 kwi 2026, 00:00 UTC

Major News Events

Geopolitical Risks Make Asia's Economic Outlook Highly Uncertain, ADB Says

10 kwi 2026, 00:00 UTC

Major News Events

Asia Regional Growth Likely to Moderate in 2026-2027, ADB Says

9 kwi 2026, 23:44 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Talks -- Market Talk

9 kwi 2026, 23:34 UTC

Market Talk

Gold Edges Lower Amid Lingering Inflation Concerns -- Market Talk

9 kwi 2026, 23:14 UTC

Market Talk

Jefferies Upbeat on Australian Miners, But Recession a Key Risk -- Market Talk

9 kwi 2026, 23:14 UTC

Market Talk

Global Equities Roundup: Market Talk

9 kwi 2026, 23:07 UTC

Market Talk

Centaurus's Supply Deal with Glencore Supports Jaguar Development -- Market Talk

9 kwi 2026, 22:54 UTC

Market Talk

Transurban Lacks Appeal as Higher Fuel Prices Slow Traffic -- Market Talk

9 kwi 2026, 22:31 UTC

Major News Events

Trump on Truth Social: 'That Is Not the Agreement We Have!'

9 kwi 2026, 22:31 UTC

Major News Events

Trump on Truth Social: 'Iran Is Doing a Very Poor Job, Dishonorable Some Would Say, of Allowing Oil to Go Through the Strait of Hormuz'

9 kwi 2026, 20:57 UTC

Major News Events

U.S. Oil Prices Are Back Near $100 After Israel Keeps Up Air Strikes on Lebanon -- Barrons.com

9 kwi 2026, 20:55 UTC

Earnings

Stryker: Believes Incident Hasn't Had, and Isn't Reasonably Likely to Have, a Material Impact on 2026 Full-Year Guidance >SYK

9 kwi 2026, 20:55 UTC

Earnings

Stryker: Determined Incident Had Material Impact on Operations, With Resulting Impact on Financial Results for 1Q >SYK

9 kwi 2026, 20:55 UTC

Earnings

Stryker: Investigation of Cybersecurity Incident Remains Ongoing >SYK

9 kwi 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

9 kwi 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 kwi 2026, 20:40 UTC

Acquisitions, Mergers, Takeovers

Blackstone Investment Positions Rowan to Continue Delivering Sustainable Data Center Capacity for World's Leading Technology Cos >BX

9 kwi 2026, 20:39 UTC

Acquisitions, Mergers, Takeovers

Blackstone Blackstone Acquired Significant Minority Stake in Rowan Digital Infrastructure >BX

9 kwi 2026, 20:39 UTC

Acquisitions, Mergers, Takeovers

Rowan Digital Infrastructure Announces Strategic Recapitalization

9 kwi 2026, 20:25 UTC

Acquisitions, Mergers, Takeovers

SBA Communications Stock Soars on Buyout Interest. What It Means for Tower Stocks. -- Barrons.com

9 kwi 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9 kwi 2026, 19:30 UTC

Major News Events

How Digital Currencies Have Helped Iran -- WSJ

Peer Comparison

Price change

AnaptysBio Inc Forecast

Price Target

By TipRanks

26.98% upside

12 Months Forecast

Average 83.22 USD 26.98%

High 140 USD

Low 50 USD

Based on 10 Wall Street analysts offering 12 month price targets forAnaptysBio Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Based on 10 analysts giving stock ratings to AnaptysBio Inc - Dist in the past 3 months.

Technical Score

By Trading Central

19.25 / 21.135Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

158 / 348 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.